Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives

European Neuropsychopharmacology

Volumn 25, Issue 10, 2015, Pages 1513-1531

  Persico, Antonio M ^a,b,j   Arango, Celso ^c,j   Buitelaar, Jan K ^d,j   Correll, Christoph U ^e   Glennon, Jeffrey C ^d   Hoekstra, Pieter J ^f,j   Moreno, Carmen ^c,j   Vitiello, Benedetto ^g   Vorstman, Jacob ^h   Zuddas, Alessandro ^i,j   Banaschewski, Tobias ^j   Castro Fornieles, Josefina ^j   Coghill, David ^k   Cohen, David ^j   Dittmann, Ralf W ^j   Fegert, Jörg M ^j   Purper Ouakil, Diane ^j   Parellada, Mara ^j   Roessner, Veit ^j  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b Mafalda Luce Center for Pervasive Developmental Disorders   (Italy)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d RADBOUD UNIVERSITY   (Netherlands)

^e ZUCKER HILLSIDE HOSPITAL   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ UNIVERSITY OF CAGLIARI   (Italy)

^j NONE

^k Dundee College   (United Kingdom)

more..

Author keywords

Autism spectrum disorder; Biomarkers; Intellectual disability; Off label use; Pharmaceutical policies; Psychopharmacology

Indexed keywords

ANTIDEPRESSANT AGENT; LONG UNTRANSLATED RNA; MICRORNA; NEUROLEPTIC AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR; PSYCHOTROPIC AGENT;

ANOREXIA NERVOSA; AUTISM; BIPOLAR DISORDER; CHILD PSYCHIATRY; CONDUCT DISORDER; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EATING DISORDER; EVIDENCE BASED PRACTICE; HEALTH CARE NEED; HUMAN; HUMAN GENETICS; INTELLECTUAL IMPAIRMENT; MENTAL DISEASE; MULTICENTER STUDY (TOPIC); NONHUMAN; OFF LABEL DRUG USE; ONSET AGE; PLACEBO EFFECT; PLURIPOTENT STEM CELL; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOCIAL ACCEPTANCE; TREATMENT RESPONSE; ADOLESCENT; CHILD; CLINICAL TRIAL (TOPIC); EUROPE; LEGISLATION AND JURISPRUDENCE; MENTAL DISORDERS;

ADOLESCENT; CHILD; CLINICAL TRIALS AS TOPIC; EUROPE; HUMANS; MENTAL DISORDERS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 84943348943     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.06.009     Document Type: Review

References (152)

1. Amminger G.P., Mechelli A., Rice S., Kim S.W., Klier C.M., McNamara R.K., Berk M., McGorry P.D., Schäfer M.R. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. Transl. Psychiatry 2015, 5:e495.
2. Arango C., Rapado-Castro M., Reig S., Castro-Fornieles J., González-Pinto A., Otero S., Baeza I., Moreno C., Graell M., Janssen J., Parellada M., Moreno D., Bargalló N., Desco M. Progressive brain changes in children and adolescents with first-episode psychosis. Arch. Gen. Psychiatry 2012, 69:16-26.
3. Arango C., Giráldez M., Merchán-Naranjo J., Baeza I., Castro-Fornieles J., Alda J.-A., Martínez-Cantarero C., Moreno C., de Andrés P., Cuerda C., de la Serna E., Correll C.U., Fraguas D., Parellada M. Second-generation antipsychotics in children and adolescents: a six-month prospective cohort study in drug-naive patients. J. Am. Acad. Child Adolesc. Psychiatry 2014, 53(11):1179-1190.
4. Arango C., Fraguas D., Parellada M. Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders. Schizophr. Bull. 2014, 40(Suppl. 2):S138-S146.
5. Arango C. Present and future of developmental neuropsychopharmacology. Eur. Neuropsychopharmacol. 2015, 25(5):703-712.
6. Athanasiou M.C., Dettling M., Cascorbi I., Mosyagin I., Salisbury B.A., Pierz K.A., Zou W., Whalen H., Malhotra A.K., Lencz T., Gerson S.L., Kane J.M., Reed C.R. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J. Clin. Psychiatry 2011, 72(4):458-463.
7. Atkinson S.D., Prakash A., Zhang Q., Pangallo B.A., Bangs M.E., Emslie G.J., March J.S. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J. Child Adolesc. Psychopharmacol. 2014, 24:180-189.
8. Awudu G.A., Besag F.M. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update. Drug Saf. 2014, 37(9):661-676.
9. Barbaresi W.J., Katusic S.K., Colligan R.C., Weaver A.L., Leibson C.L., Jacobsen S.J. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J. Dev. Behav. Pediatr. 2014, 35(7):448-457.
10. Barkley R.A., Fischer M., Smallish L., Fletcher K. Young adult follow-up of hyperactive children: antisocial activities and drug use. J. Child Psychol. Psychiatry 2004, 45(2):195-211.
11. Batstra L., Frances A. Diagnostic inflation: causes and a suggested cure. J. Nerv. Ment. Dis. 2012, 200(6):474-479.
12. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27:370-377.
13. Berko E.R., Suzuki M., Beren F., Lemetre C., Alaimo C.M., Calder R.B., Ballaban-Gil K., Gounder B., Kampf K., Kirschen J., Maqbool S.B., Momin Z., Reynolds D.M., Russo N., Shulman L., Stasiek E., Tozour J., Valicenti-McDermott M., Wang S., Abrahams B.S., Hargitai J., Inbar D., Zhang Z., Buxbaum J.D., Molholm S., Foxe J.J., Marion R.W., Auton A., Greally J.M. Mosaic epigenetic dysregulation of ectodermal cells in autism spectrum disorder. PLoS Genet. 2014, 10(5):e1004402.
14. Brennand K.J., Simone A., Tran N., Gage F.H. Modeling psychiatric disorders at the cellular and network levels. Mol. Psychiatry 2012, 17(12):1239-1253.
15. Bridge J.A., Iyengar S., Salary C.B., Barbe R.P., Birmaher B., Pincus H.A., Ren L., Brent D.A. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007, 297:1683-1696.
16. Bridge J.A., Birmaher B., Iyengar S., Barbe R.P., Brent D.A. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am. J. Psychiatry 2009, 166(1):42-49.
17. Bruining H., Eijkemans M.J., Kas M.J., Curran S.R., Vorstman J.A., Bolton P.F. Behavioral signatures related to genetic disorders in autism. Mol. Autism 2014, 5(1):11.
18. Chue P., Lalonde J.K. Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatr. Dis. Treat. 2014, 10:777-789.
19. Clifford S., Dissanayake C., Bui Q.M., Huggins R., Taylor A.K., Loesch D.Z. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J. Autism Dev. Disord. 2007, 37(4):738-747.
20. Cocks G., Curran S., Gami P., Uwanogho D., Jeffries A.R., Kathuria A., Lucchesi W., Wood V., Dixon R., Ogilvie C., Steckler T., Price J. The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders. Psychopharmacology (Berl.) 2014, 231(6):1079-1088.
21. Conroy S., Choonara I., Impicciatore P., Mohn A., Arnell H., Rane A., Knoeppel C., Seyberth H., Pandolfini C., Raffaelli M.P., Rocchi F., Bonati M., Jong G., de Hoog M., van den Anker J. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000, 320(7227):79-82.
22. Correll C.U. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J. Am. Acad. Child Adolesc. Psychiatry 2008, 47(1):9-20.
23. Correll C.U., Manu P., Olshanskiy V., Napolitano B.A., Kane J.M., Malhotra A.K. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302:1765-1773.
24. Correll C.U., Hauser M., Auther A.M., Cornblatt B.A. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J. Child Psychol. Psychiatry 2010, 51(4):390-431.
25. Correll C.U., Kratochvil C.J., March J.S. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J. Clin. Psychiatry 2011, 72(5):655-670.
26. Costello E.J., Copeland W., Angold A. Trends in psychopathology across the adolescent years: what changes when children become adolescents, and when adolescents become adults?. J. Child Psychol. Psychiatry 2011, 52(10):1015-1025.
27. Crowther C.A., Hiller J.E., Doyle L.W., Haslam R.R., Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003, 290(20):2669-2676.
28. Dalsgaard S., Nielsen H.S., Simonsen M. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study. J. Child Adolesc. Psychopharmacol. 2013, 23(7):432-439.
29. De Rubeis S., He X., Goldberg A.P., Poultney C.S., Samocha K., Cicek A.E., Kou Y., Liu L., Fromer M., Walker S., Singh T., Klei L., Kosmicki J., Shih-Chen F., Aleksic B., Biscaldi M., Bolton P.F., Brownfeld J.M., Cai J., Campbell N.G., Carracedo A., Chahrour M.H., Chiocchetti A.G., Coon H., Crawford E.L., Curran S.R., Dawson G., Duketis E., Fernandez B.A., Gallagher L., Geller E., Guter S.J., Hill R.S., Ionita-Laza J., Jimenz Gonzalez P., Kilpinen H., Klauck S.M., Kolevzon A., Lee I., Lei I., Lei J., Lehtimäki T., Lin C.F., Ma'ayan A., Marshall C.R., McInnes A.L., Neale B., Owen M.J., Ozaki N., Parellada M., Parr J.R., Purcell S., Puura K., Rajagopalan D., Rehnström K., Reichenberg A., Sabo A., Sachse M., Sanders S.J., Schafer C., Schulte-Rüther M., Skuse D., Stevens C., Szatmari P., Tammimies K., Valladares O., Voran A., Li-San W., Weiss L.A., Willsey A.J., Yu T.W., Yuen R.K., DDD Study; Homozygosity Mapping Collaborative for Autism; UK10K Consortium, Cook E.H., Freitag C.M., Gill M., Hultman C.M., Lehner T., Palotie A., Schellenberg G.D., Sklar P., State M.W., Sutcliffe J.S., Walsh C.A., Scherer S.W., Zwick M.E., Barett J.C., Cutler D.J., Roeder K., Devlin B., Daly M.J., Buxbaum J.D. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014, 515(7526):209-215.
30. de Vrij F.M., Levenga J., van der Linde H.C., Koekkoek S.K., De Zeeuw C.I., Nelson D.L., Oostra B.A., Willemsen R. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol. Dis. 2008, 31:127-132.
31. Doers M.E., Musser M.T., Nichol R., Berndt E.R., Baker M., Gomez T.M., Zhang S.C., Abbeduto L., Bhattacharyya A. iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth. Stem Cells Dev. 2014, 23(15):1777-1787.
32. Dölen G., Osterweil E., Rao B.S., Smith G.B., Auerbach B.D., Chattarji S., Bear M.F. Correction of fragile X syndrome in mice. Neuron 2007, 56(6):955-962.
33. Dörks M., Langner I., Dittmann U., Timmer A., Garbe E. Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study. Eur. Child Adolesc. Psychiatry 2013, 22(8):511-518.
34. Eberhart D.E., Malter H.E., Feng Y., Warren S.T. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum. Mol. Genet. 1996, 5(8):1083-1091.
35. Egberts K., Karwautz A., Plener P.L., Mehler-Wex C., Kölch M., Dang S.Y., Taurines R., Romanos M., Gerlach M. Pharmacovigilance in child and adolescent psychiatry. Z. Kinder Jugendpsychiatr. Psychother. 2015, 43(1):21-28.
36. Elia J., Glessner J.T., Wang K., Takahashi N., Shtir C.J., Hadley D., Sleiman P.M., Zhang H., Kim C.E., Robison R., Lyon G.J., Flory J.H., Bradfield J.P., Imielinski M., Hou C., Frackelton E.C., Chiavacci R.M., Sakurai T., Rabin C., Middleton F.A., Thomas K.A., Garris M., Mentch F., Freitag C.M., Steinhausen H.C., Todorov A.A., Reif A., Rothenberger A., Franke B., Mick E.O., Roeyers H., Buitelaar J., Lesch K.P., Banaschewski T., Ebstein R.P., Mulas F., Oades R.D., Sergeant J., Sonuga-Barke E., Renner T.J., Romanos M., Romanos J., Warnke A., Walitza S., Meyer J., Pálmason H., Seitz C., Loo S.K., Smalley S.L., Biederman J., Kent L., Asherson P., Anney R.J., Gaynor J.W., Shaw P., Devoto M., White P.S., Grant S.F., Buxbaum J.D., Rapoport J.L., Williams N.M., Nelson S.F., Faraone S.V., Hakonarson H. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat. Genet. 2011, 44(1):78-84.
37. Emslie G.J., Prakash A., Zhang Q., Pangallo B.A., Bangs M.E., March J.S. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J. Child Adolesc. Psychopharmacol. 2014, 24:170-179.
38. European Medicines Agency, 2010. Committee for Medicinal Products for Human use (CHMP). Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD). Available at (July 22, 2010). http://www.ema.europa.eu/docs/en_GB/%20document_library/Scientific_guideline/2010/08/WC500095686.pdf.
39. European Medicines Agency, 2012. Committee for Medicinal Products for Human use (CHMP). Guideline on Clinical Investigation of Medicinal Products, Including Depot Preparations in the Treatment of Schizophrenia. Available at (September 20, 2012). http://www.ema.europa.eu/docs/en_GB/%20document_library/Scientific_guideline/2012/10/WC500133437.pdf.
40. European Medicines Agency, 2013a. Committee for Medicinal Products for Human use (CHMP). Successes of the Paediatric Regulation After 5 Years-August 2007-December 2012. Available at (June 6, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/06/WC500143984.pdf.
41. European Medicines Agency, 2013b. Committee for Medicinal Products for Human use (CHMP). Concept Paper on the Development of Medicinal Products for the Treatment of Autism Spectrum Disorder. Available at (March 21, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/04/WC500141490.pdf.
42. European Medicines Agency, 2013c. Committee for Medicinal Products for Human use (CHMP). Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD). Available at (May 30, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/08/WC500095686.pdf.
43. Fabbri C., Minarini A., Niitsu T., Serretti A. Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Expert Opin. Drug Metab. Toxicol. 2014, 10(8):1093-1118.
44. Findling R.L., McNamara N.K., Branicky L.A., Schluchter M.D., Lemon E., Blumer J.L. A double-blind pilot study of risperidone in the treatment of conduct disorder. J. Am. Acad. Child Adolesc. Psychiatry 2000, 39(4):509-516.
45. Findling R.L., Cavuş I., Pappadopulos E., Vanderburg D.G., Schwartz J.H., Gundapaneni B.K., Del Bello M.P. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol. 2013, 23(8):545-557.
46. Fraguas D., Correll C.U., Merchán-Naranjo J., Rapado-Castro M., Parellada M., Moreno C., Arango C. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur. Neuropsychopharmacol. 2011, 21(8):621-645.
47. Fraguas D., Gonzalez-Pinto A., Micó J.A., Reig S., Parellada M., Martínez-Cengotitabengoa M., Castro-Fornieles J., Rapado-Castro M., Baeza I., Janssen J., Desco M., Leza J.C., Arango C. Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study. Schizophr. Res. 2012, 137:58-65.
48. Frans E.M., Sandin S., Reichenberg A., Långström N., Lichtenstein P., McGrath J.J., Hultman C.M. Autism risk across generations: a population-based study of advancing grandpaternal and paternal age. JAMA Psychiatry 2013, 70(5):516-521.
49. Franz D.N., Belousova E., Sparagana S., Bebin E.M., Frost M., Kuperman R., Witt O., Kohrman M.H., Flamini J.R., Wu J.Y., Curatolo P., de Vries P.J., Berkowitz N., Anak O., Niolat J., Jozwiak S. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 2014, 15(13):1513-1520.
50. Fu Y.H., Kuhl D.P., Pizzuti A., Pieretti M., Sutcliffe J.S., Richards S., Verkerk A.J., Holden J.J., Fenwick R.G., Warren S.T., et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991, 67(6):1047-1058.
51. Galling B., Correll C.U. Do antipsychotics increase diabetes risk in children and adolescents?. Expert Opin. Drug Saf 2015, 14(2):219-241.
52. Geddes J.R. Large simple trials in psychiatry: providing reliable answers to important clinical questions. Epidemiol. Psichiatr. Soc. 2005, 14:122-126.
53. Gerlach M., Grünblatt E., Lange K.W. Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?. Atten. Defic. Hyperact. Disord. 2013, 5(2):71-81.
54. Germinario E.A., Arcieri R., Bonati M., Zuddas A., Masi G., Vella S., Chiarotti F., Panei P., Italian ADHD Regional Reference Centers Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. J. Child Adolesc. Psychopharmacol. 2013, 23(7):440-447.
55. Ghelani H.S., Rachchh M.A., Gokani R.H. MicroRNAs as newer therapeutic targets: a big hope from a tiny player. J. Pharmacol. Pharmacother. 2012, 3(3):217-227.
56. Ghosh A., Michalon A., Lindemann L., Fontoura P., Santarelli L. Drug discovery for autism spectrum disorder: challenges and opportunities. Nat. Rev. Drug Discovery 2013, 12(10):777-790.
57. Glennon J., Purper-Ouakil D., Bakker M., Zuddas A., Hoekstra P., Schulze U., Castro-Fornieles J., Santosh P.J., Arango C., Kölch M., Coghill D., Flamarique I., Penzol M.J., Wan M., Murray M., Wong I.C., Danckaerts M., Bonnot O., Falissard B., Masi G., Fegert J.M., Vicari S., Carucci S., Dittmann R.W., Buitelaar J.K., PERS Consortium Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. Eur. Child Adolesc. Psychiatry 2014, 23(12):1149-1160.
58. Hall S.S., Lightbody A.A., Reiss A.L. Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome. Am. J. Ment. Retard. 2008, 113(1):44-53.
59. Harding M.J., McGraw H.F., Nechiporuk A. The roles and regulation of multicellular rosette structures during morphogenesis. Development 2014, 141(13):2549-2558.
60. Harfterkamp M., van de Loo-Neus G., Minderaa R.B., van der Gaag R.J., Escobar R., Schacht A., Pamulapati S., Buitelaar J.K., Hoekstra P.J. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J. Am. Acad. Child Adolesc. Psychiatry 2012, 51(7):733-741.
61. Horváth S., Mirnics K. Schizophrenia as a disorder of molecular pathways. Biol. Psychiatry 2015, 77(1):22-28.
62. Huhn M., Tardy M., Spineli L.M., Kissling W., Förstl H., Pitschel-Walz G., Leucht C., Samara M., Dold M., Davis J.M., Leucht S. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry 2014, 71(6):706-715.
63. Huttenlocher P.R. Synaptic density in human frontal cortex-developmental changes and the effects of aging. Brain Res. 1979, 163:195-205.
64. Jacquemont S., Curie A., des Portes V., Torrioli M.G., Berry-Kravis E., Hagerman R.J., Ramos F.J., Cornish K., He Y., Paulding C., Neri G., Chen F., Hadjikhani N., Martinet D., Meyer J., Beckmann J.S., Delange K., Brun A., Bussy G., Gasparini F., Hilse T., Floesser A., Branson J., Bilbe G., Johns D., Gomez-Mancilla B. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med. 2011, 3,. 64ra1.
65. Jacquemont S., Berry-Kravis E., Hagerman R., von Raison F., Gasparini F., Apostol G., Ufer M., Des Portes V., Gomez-Mancilla B. The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl.) 2014, 231(6):1237-1250.
66. Jeste S.S., Geschwind D.H. Disentangling the heterogeneity of autism spectrum disorder through genetic findings. Nat. Rev. Neurol. 2014, 10(2):74-81.
67. Kalverdijk L.J., Tobi H., van den Berg P.B., Buiskool J., Wagenaar L., Minderaa R.B., de Jong-van den Berg L.T. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr. Serv. 2008, 59:554-560.
68. Kas M.J., Glennon J.C., Buitelaar J., Ey E., Biemans B., Crawley J., Ring R.H., Lajonchere C., Esclassan F., Talpos J., Noldus L.P., Burbach J.P., Steckler T. Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives. Psychopharmacology (Berl.) 2014, 231(6):1125-1146.
69. Kaufmann, W.E., et al. 2013. Randomized, Controlled, Phase 2 Trial of STX209 (Arbaclofen) for Social Function in Autism Spectrum Disorder. 42nd Annual Meeting of the Child Neurology Society, Austin (TX), Abstract PS1-6.
70. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62(6):593-602.
71. Khwaja O.S., Ho E., Barnes K.V., O'Leary H.M., Pereira L.M., Finkelstein Y., Nelson C.A., Vogel-Farley V., DeGregorio G., Holm I.A., Khatwa U., Kapur K., Alexander M.E., Finnegan D.M., Cantwell N.G., Walco A.C., Rappaport L., Gregas M., Fichorova R.N., Shannon M.W., Sur M., Kaufmann W.E. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc. Natl. Acad. Sci. U.S.A. 2014, 111(12):4596-4601.
72. Kitchener D.W., Wu J.C. Induced pluripotent stem cells. JAMA 2015, 313(16):1613-1614.
73. Koelch M., Prestel A., Singer H., Keller F., Fegert J.M., Schlack R., Hoelling H., Knopf H. Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns. J. Child Adolesc. Psychopharmacol. 2009, 19,:765-770.
74. Konstenius M., Jayaram-Lindström N., Guterstam J., Beck O., Philips B., Franck J. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction 2014, 109(3):440-449.
75. Krey J.F., Paşca S.P., Shcheglovitov A., Yazawa M., Schwemberger R., Rasmusson R., Dolmetsch R.E. Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons. Nat. Neurosci. 2013, 16(2):201-209.
76. Krueger D.A., Wilfong A.A., Holland-Bouley K., Anderson A.E., Agricola K., Tudor C., Mays M., Lopez C.M., Kim M.O., Franz D.N. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann. Neurol. 2013, 74(5):679-687.
77. Krützfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438(7068):685-689.
78. Leblond C.S., Heinrich J., Delorme R., Proepper C., Betancur C., Huguet G., Konyukh M., Chaste P., Ey E., Rastam M., Anckarsäter H., Nygren G., Gillberg I.C., Melke J., Toro R., Regnault B., Fauchereau F., Mercati O., Lemière N., Skuse D., Poot M., Holt R., Monaco A.P., Järvelä I., Kantojärvi K., Vanhala R., Curran S., Collier D.A., Bolton P., Chiocchetti A., Klauck S.M., Poustka F., Freitag C.M., Waltes R., Kopp M., Duketis E., Bacchelli E., Minopoli F., Ruta L., Battaglia A., Mazzone L., Maestrini E., Sequeira A.F., Oliveira B., Vicente A., Oliveira G., Pinto D., Scherer S.W., Zelenika D., Delepine M., Lathrop M., Bonneau D., Guinchat V., Devillard F., Assouline B., Mouren M.C., Leboyer M., Gillberg C., Boeckers T.M., Bourgeron T. Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet. 2012, 8(2):e1002521.
79. Lee F.S., Heimer H., Giedd J.N., Lein E.S., Šestan N., Weinberger D.R., Casey B.J. Mental health. Adolescent mental health-opportunity and obligation. Science 2014, 346(6209):547-549.
80. Lett T.A., Chakravarty M.M., Felsky D., Brandl E.J., Tiwari A.K., Gonçalves V.F., Rajji T.K., Daskalakis Z.J., Meltzer H.Y., Lieberman J.A., Lerch J.P., Mulsant B.H., Kennedy J.L., Voineskos A.N. The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Mol. Psychiatry 2013, 18(4):443-450.
81. Lichtenstein P., Halldner L., Zetterqvist J., Sjölander A., Serlachius E., Fazel S., Långström N., Larsson H. Medication for attention deficit-hyperactivity disorder and criminality. N. Engl. J. Med. 2012, 367(21):2006-2014.
82. Liu J.S. Molecular genetics of neuronal migration disorders. Curr. Neurol. Neurosci. Rep. 2011, 11(2):171-178.
83. Lo Sardo V., Zuccato C., Gaudenzi G., Vitali B., Ramos C., Tartari M., Myre M.A., Walker J.A., Pistocchi A., Conti L., Valenza M., Drung B., Schmidt B., Gusella J., Zeitlin S., Cotelli F., Cattaneo E. An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin. Nat. Neurosci. 2012, 15(5):713-721.
84. Loth, E., Spooren, W., Ham, L.M., Isaac, M.B., Auriche-Benichou, C., Banaschewski, T., Baron-Cohen, S., Broich, K., Bölte, S., Bourgeron, T., Charman, T., Collier, D., de Andres-Trelles, F., Durston, S., Ecker, C., Elferink, A., Haberkamp, M., Hemmings, R., Johnson, M.H., Jones, E.J.H., Khwaja, O.S., Lenton S., Mason, L., Mantua, V., Meyer-Lindenberg, A., Lombardo, M.V., O'Dwyer, L., Okamoto, K., Pani, L., Persico, A.M., Simonoff, E., Tauscher-Wisniewski, S., Vamvakas, S., Williams, S., Buitelaar, J.K., Murphy, D.G.M., 2015. the EU-AIMS LEAP group, Identification and Validation of Biomarkers for Autism Spectrum Disorders: Towards a Shared Understanding between Academia, Industry and Regulatory Authorities. Nat. Rev. Drug Discov., submitted.
85. Man K.K., Chan E.W., Coghill D., Douglas I., Ip P., Leung L.P., Tsui M.S., Wong W.H., Wong I.C. Methylphenidate and the risk of trauma. Pediatrics 2015, 135:40-48.
86. Manolis E., Koch A., Deforce D., Vamvakas S. The European Medicines Agency experience with biomarker qualification. Methods Mol. Biol. 2015, 1243:255-272.
87. March J., Kratochvil C., Clarke G., Beardslee W., Derivan A., Emslie G., Green E.P., Heiligenstein J., Hinshaw S., Hoagwood K., Jensen P., Lavori P., Leonard H., McNulty J., Michaels M.A., Mossholder A., Osher T., Petti T., Prentice E., Vitiello B., Wells K. AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology. J. Am. Acad. Child Adolesc. Psychiatry 2004, 43(8):1046-1056.
88. Marcus R.N., Owen R., Kamen L., Manos G., McQuade R.D., Carson W.H., Aman M.G. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48(11):1110-1119.
89. Menard M.L., Thümmler S., Auby P., Askenazy F. Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents. Child Adolesc. Psychiatry Ment. Health 2014, 8:18.
90. Meng L., Ward A.J., Chun S., Bennett C.F., Beaudet A.L., Rigo F. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature 2015, 518(7539):409-412.
91. Meza-Sosa K.F., Pedraza-Alva G., Pérez-Martínez L. microRNAs: key triggers of neuronal cell fate. Front. Cell. Neurosci. 2014, 25(8):175.
92. Molina B.S., Hinshaw S.P., Swanson J.M., Arnold L.E., Vitiello B., Jensen P.S., Epstein J.N., Hoza B., Hechtman L., Abikoff H.B., Elliott G.R., Greenhill L.L., Newcorn J.H., Wells K.C., Wigal T., Gibbons R.D., Hur K., Houck P.R., MTA Cooperative Group The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48(5):484-500.
93. Moreno C., Arango C., Parellada M., Shaffer D., Bird H. Antidepressants in child and adolescent depression: where are the bugs?. Acta Psychiatr. Scand. 2007, 115(3):184-195.
94. Moreno C., Nuevo R., Chatterji S., Verdes E., Arango C., Ayuso-Mateos J.L. Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey. World Psychiatry 2013, 12(3):251-257.
95. Murphy A.L., Gardner D.M., Cooke C., Kisely S., Hughes J., Kutcher S.P. Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study. BMC Psychiatry 2013, 13:198.
96. Murray M.L., Insuk S., Banaschewski T., Neubert A.C., McCarthy S., Buitelaar J.K., Coghill D., Dittmann R.W., Konrad K., Panei P., Rosenthal E., Sonuga-Barke E.J., Wong I.C. An inventory of European data sources for the long-term safety evaluation of methylphenidate. Eur. Child Adolesc. Psychiatry 2013, 22(10):605-618.
97. Naudet F., Maria A.S., Falissard B. Antidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies. PLoS One 2011, 6(6):e20811.
98. Nymberg C., Jia T., Lubbe S., Ruggeri B., Desrivieres S., Barker G., Büchel C., Fauth-Buehler M., Cattrell A., Conrod P., Flor H., Gallinat J., Garavan H., Heinz A., Ittermann B., Lawrence C., Mann K., Nees F., Salatino-Oliveira A., Paillère Martinot M.L., Paus T., Rietschel M., Robbins T., Smolka M., Banaschewski T., Rubia K., Loth E., Schumann G., IMAGEN Consortium Neural mechanisms of attention-deficit/hyperactivity disorder symptoms are stratified by MAOA genotype. Biol. Psychiatry 2013, 74(8):607-614.
99. Olfson M., Blanco C., Liu S.M., Wang S., Correll C.U. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch. Gen. Psychiatry 2012, 69(12):1247-1256.
100. Olfson M., Blanco C., Wang S., Laje G., Correll C.U. National trends in the mental health care of children, adolescents, and adults by office-based physicians. JAMA Psychiatry 2014, 71:81-90.
101. Orloff J., Douglas F., Pinheiro J., Levinson S., Branson M., Chaturvedi P., Ette E., Gallo P., Hirsch G., Mehta C., Patel N., Sabir S., Springs S., Stanski D., Evers M.R., Fleming E., Singh N., Tramontin T., Golub H. The future of drug development: advancing clinical trial design. Nat. Rev. Drug Discovery 2009, 8(12):949-957.
102. Palanca-Maresca I., Ruiz-Antorán B., Centeno-Soto G., Jiménez-Fernandez S., García-Murillo L., Siles A., Villagrá S., Blasco-Fontecilla H., Iruela-Cuadrado L., Roman-Riechman E., Avendaño-Solá C., Correll C.U. SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics. Springerplus 2014, 3:187.
103. Pandya C.D., Howell K.R., Pillai A. Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 46:214-223.
104. Parellada M., Penzol M.J., Pina L., Moreno C., Gonzalez-Vioque E., Zalsman G., Arango C. The neurobiology of autism spectrum disorders. Eur. Psychiatry 2014, 29:11-19.
105. Partridge B., Lucke J., Hall W. Over-diagnosed and over-treated: a survey of Australian public attitudes towards the acceptability of drug treatment for depression and ADHD. BMC Psychiatry 2014, 14:74.
106. Persico A.M., Napolioni V. Autism genetics. Behav. Brain Res. 2013, 251:95-112.
107. Persico A.M., Merelli S. Environmental factors and autism spectrum disorder. Curr. Dev. Disord. Rep. 2014, 1:8-19.
108. Pierre J.M. Mental illness and mental health: is the glass half empty or half full? Can. J. Psychiatry 2012, 57(11):651-658.
109. Pinto D., Delaby E., Merico D., Barbosa M., Merikangas A., Klei L., Thiruvahindrapuram B., Xu X., Ziman R., Wang Z., Vorstman J.A., Thompson A., Regan R., Pilorge M., Pellecchia G., Pagnamenta A.T., Oliveira B., Marshall C.R., Magalhaes T.R., Lowe J.K., Howe J.L., Griswold A.J., Gilbert J., Duketis E., Dombroski B.A., De Jonge M.V., Cuccaro M., Crawford E.L., Correia C.T., Conroy J., Conceição I.C., Chiocchetti A.G., Casey J.P., Cai G., Cabrol C., Bolshakova N., Bacchelli E., Anney R., Gallinger S., Cotterchio M., Casey G., Zwaigenbaum L., Wittemeyer K., Wing K., Wallace S., van Engeland H., Tryfon A., Thomson S., Soorya L., Rogé B., Roberts W., Poustka F., Mouga S., Minshew N., McInnes L.A., McGrew S.G., Lord C., Leboyer M., Le Couteur A.S., Kolevzon A., Jiménez González P., Jacob S., Holt R., Guter S., Green J., Green A., Gillberg C., Fernandez B.A., Duque F., Delorme R., Dawson G., Chaste P., Café C., Brennan S., Bourgeron T., Bolton P.F., Bölte S., Bernier R., Baird G., Bailey A.J., Anagnostou E., Almeida J., Wijsman E.M., Vieland V.J., Vicente A.M., Schellenberg G.D., Pericak-Vance M., Paterson A.D., Parr J.R., Oliveira G., Nurnberger J.I., Monaco A.P., Maestrini E., Klauck S.M., Hakonarson H., Haines J.L., Geschwind D.H., Freitag C.M., Folstein S.E., Ennis S., Coon H., Battaglia A., Szatmari P., Sutcliffe J.S., Hallmayer J., Gill M., Cook E.H., Buxbaum J.D., Devlin B., Gallagher L., Betancur C., Scherer S.W. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am. J. Hum. Genet. 2014, 94(5):677-694.
110. Poelmans G., Pauls D.L., Buitelaar J.K., Franke B. Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am. J. Psychiatry 2011, 168(4):365-377.
111. Poelmans G., Franke B., Pauls D.L., Glennon J.C., Buitelaar J.K. AKAPs integrate genetic findings for autism spectrum disorders. Transl. Psychiatry 2013, 3:e270.
112. Politte L.C., Henry C.A., McDougle C.J. Psychopharmacological interventions in autism spectrum disorder. Harv. Rev. Psychiatry 2014, 22(2):76-92.
113. Politte L.C., McDougle C.J. Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl.) 2014, 231(6):1023-1036.
114. Qin B., Zhang Y., Zhou X., Cheng P., Liu Y., Chen J., Fu Y., Luo Q., Xie P. Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability. Clin. Ther. 2014, 36(7):1087-1095.
115. Rani F., Murray M.L., Byrne P.J., Wong I.C. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008, 121:1002-1009.
116. Reiersen A.M., Handen B. Commentary on Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Evid. Based Child Health 2011, 6:1082-1085.
117. Research Units on Pediatric Psychopharmacology Autism Network Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch. Gen. Psychiatry 2005, 62:1266-1274.
118. Ruel J.M., Hickey C.P. Are too many children being treated with methylphenidate?. Can. J. Psychiatry 1992, 37(8):570-572.
119. Ruggeri B., Sarkans U., Schumann G., Persico A.M. Biomarkers in autism spectrum disorder: the old and the new. Psychopharmacology (Berl.) 2014, 231(6):1201-1216.
120. Salum G.A., Polanczyk G.V., Miguel E.C., Rohde L.A. Effects of childhood development on late-life mental disorders. Curr. Opin. Psychiatry 2010, 23(6):498-503.
121. Schaefer A., O'Carroll D., Tan C.L., Hillman D., Sugimori M., Llinas R., Greengard P. Cerebellar neurodegeneration in the absence of microRNAs. J. Exp. Med. 2007, 204(7):1553-1558.
122. Schmäl C., Becker K., Berg R., Brünger M., Lehmkuhl G., Oehler K.U., Ruppert T., Staudter C., Trott G.E., Dittmann R.W. Pediatric psychopharmacological research in the post EU regulation 1901/2006 era. Z. Kinder Jugendpsychiatr. Psychother. 2014, 42(6):441-449.
123. Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427.
124. Schumann G., Binder E.B., Holte A., de Kloet E.R., Oedegaard K.J., Robbins T.W., Walker-Tilley T.R., Bitter I., Brown V.J., Buitelaar J., Ciccocioppo R., Cools R., Escera C., Fleischhacker W., Flor H., Frith C.D., Heinz A., Johnsen E., Kirschbaum C., Klingberg T., Lesch K.P., Lewis S., Maier W., Mann K., Martinot J.L., Meyer-Lindenberg A., Müller C.P., Müller W.E., Nutt D.J., Persico A., Perugi G., Pessiglione M., Preuss U.W., Roiser J.P., Rossini P.M., Rybakowski J.K., Sandi C., Stephan K.E., Undurraga J., Vieta E., van der Wee N., Wykes T., Haro J.M., Wittchen H.U. Stratified medicine for mental disorders. Eur. Neuropsychopharmacol. 2014, 24:5-50.
125. Simonoff E., Pickles A., Charman T., Chandler S., Loucas T., Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J. Am. Acad. Child Adolesc. Psychiatry 2008, 47:921-929.
126. Simonoff E., Taylor E., Baird G., Bernard S., Chadwick O., Liang H., Whitwell S., Riemer K., Sharma K., Sharma S.P., Wood N., Kelly J., Golaszewski A., Kennedy J., Rodney L., West N., Walwyn R., Jichi F. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. J. Child Psychol. Psychiatry 2013, 54:527-535.
127. Singh K., Connors S.L., Macklin E.A., Smith K.D., Fahey J.W., Talalay P., Zimmerman A.W. Sulforaphane treatment of autism spectrum disorder (ASD). Proc. Natl. Acad. Sci. U.S.A. 2014, 111(43):15550-15555.
128. Smoller J.W. Disorders and borders: psychiatric genetics and nosology. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2013, 162B(7):559-578.
129. Steinberg J., Webber C. The roles of FMRP-regulated genes in autism spectrum disorder: single- and multiple-hit genetic etiologies. Am. J. Hum. Genet. 2013, 93(5):825-839.
130. Steinhausen H.C. Recent international trends in psychotropic medication prescriptions for children and adolescents. Eur Child Adolesc Psychiatry 2015, 24(6):635-640.
131. Tebbenkamp A.T., Willsey A.J., State M.W., Sestan N. The developmental transcriptome of the human brain: implications for neurodevelopmental disorders. Curr. Opin. Neurol. 2014, 27(2):149-156.
132. The Deciphering Developmental Disorders Study Large-scale discovery of novel genetic causes of developmental disorders. Nature 2015, 519(7542):223-228.
133. Thomas R., Mitchell G.K., Batstra L. Attention-deficit/hyperactivity disorder: are we helping or harming?. BMJ 2013, 347:f6172.
134. Topper S., Ober C., Das S. Exome sequencing and the genetics of intellectual disability. Clin. Genet. 2011, 80(2):117-126.
135. Tsapakis E.M., Soldani F., Tondo L., Baldessarini R.J. Efficacy of antidepressants in juvenile depression: meta-analysis. Br. J. Psychiatry 2008, 193:10-17.
136. Usala T., Clavenna A., Zuddas A., Bonati M. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur. Neuropsychopharmacol. 2008, 18:62-73.
137. Vaishnavi V., Manikandan M., Tiwary B.K., Munirajan A.K. Insights on the functional impact of microRNAs present in autism-associated copy number variants. PLoS One 2013, 8(2):e56781.
138. van de Vondervoort I.I., Gordebeke P.M., Khoshab N., Tiesinga P.H., Buitelaar J.K., Kozicz T., Aschrafi A., Glennon J.C. Long non-coding RNAs in neurodevelopmental disorders. Front. Mol. Neurosci. 2013, 6:53.
139. Veenstra-VanderWeele, J., Sikich, L., Melmed, R., von Hehn J.S., Walton-Bowen K.L., Kuriyama N., Cherubini M., Zarevics P., Carpenter R.L., Bear M.F., Wang P., Cook E.H., 2013. Randomized, Controlled, Phase 2 Trial of STX209 for Social Function in ASD. International Meeting for Autism Research, Donostia (Spain), Abstract 102.001.
140. Vierbuchen T., Ostermeier A., Pang Z.P., Kokubu Y., Südhof T.C., Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463(7284):1035-1041.
141. Vitiello B., Grabb M. The development of targeted neurobiological therapies in child and adolescent psychiatry. J. Am. Acad. Child Adolesc. Psychiatry 2013, 52:775-779.
142. Vorstman J.A., Ophoff R.A. Genetic causes of developmental disorders. Curr. Opin. Neurol. 2013, 26(2):128-136.
143. Vorstman J.A., Spooren W., Persico A.M., Collier D.A., Aigner S., Jagasia R., Glennon J.C., Buitelaar J.K. Using genetic findings in autism for the development of new pharmaceutical compounds. Psychopharmacology (Berl.) 2014, 231(6):1063-1078.
144. Yamanaka S. Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif. 2008, 41(Suppl. 1):51-56.
145. Yan Q.J., Rammal M., Tranfaglia M., Bauchwitz R.P. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005, 49:1053-1066.
146. Watson G.L., Arcona A.P., Antonuccio D.O., Healy D. Shooting the messenger: the case of ADHD. J. Contemp. Psychother. 2014, 44:43-52.
147. Weitz A.J., Fang Z., Lee H.J., Fisher R.S., Smith W.C., Choy M., Liu J., Lin P., Rosenberg M., Lee J.H. Optogenetic fMRI reveals distinct, frequency-dependent networks recruited by dorsal and intermediate hippocampus stimulations. NeuroImage 2015, 107:229-241.
148. Williams K., Wheeler D.M., Silove N., Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst. Rev. 2010, 8,. CD004677.
149. Wisniewski S.R., Rush A.J., Nierenberg A.A., Gaynes B.N., Warden D., Luther J.F., McGrath P.J., Lavori P.W., Thase M.E., Fava M., Trivedi M.H. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am. J. Psychiatry 2009, 166(5):599-607.
150. Zito J.M., Burcu M., Ibe A., Safer D.J., Magder L.S. Antipsychotic use by medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade. Psychiatr. Serv. 2013, 64:223-229.
151. Zuddas A., Zanni A., Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur. Neuropsychopharmacol. 2011, 21:600-620.
152. Zwi M., Ramchandani P., Joughin C. Evidence and belief in ADHD. BMJ 2000, 321(7267):975-976.